The natural abundance of lambda2-light chains in inbred mice by unknown
THE NATURAL ABUNDANCE OF ?~2-LIGHT CHAINS 
IN INBRED MICE* 
BY TOM  COTNER  AND HERMAN  N.  EISEN 
From the Department  of Biology and the Center for Cancer Research, Massachusetts  Institute of Technology, 
Cambridge, Massachusetts  02139 
A  small fraction of the light (L) 1 chains of mouse immunoglobulins (Igs) are of the 
X-type  (1).  Of the  -~  22  X-chains  from  mouse  myeloma  tumors  whose  amino  acid 
sequences have been partially or fully determined, all but one have the same constant 
(C)  domain  sequence  (2,  3).  The exception, L 3t5, is the light chain  of the  myeloma 
protein (M315)  produced by plasmacytoma MOPC-315.  L 315, called a  X2-ehain  (4), 
differs from the other mouse h-chains, called X1, at 29 of 110 positions in the C  region 
and,  compared to  the prototype Xl-chain  (L1°4),  at  1 1 positions in the variable  (V) 
region (5). 
The mouse in which MOPC-315  arose was of the BALB/c 2 type; it derived from 
the  seventh  backcross  to  purebred  BALB/c  mice  beginning  with  a  (BALB/c-  × 
C57BI/Ka)  F1 hybrid (6).  Because other X2-chains have so far not been described in 
BALB/c myelomas, it has long seemed possible that the L 3a~ chain might be an allelic 
variant  (of C57BI/Ka origin)  of the Xl-chains produced in BALB/c.  However, with 
so  many  scattered  C-domain  amino  acid  differences between  X1  and  L 3t~  a  more 
attractive  possibility is  that  L axg represents  a  rarely expressed  L-chain  isotype, X2, 
rather than a  X-allotype (7). 
Accordingly, the object of the present study was to establish whether L315-1ike (X2) 
chains exist in  Igs from  BALB/c  and  other mouse  strains and,  if so,  at  what  level. 
Advantage was taken of the Fv fragment of M315  (V~  15  and V~ 5) to obtain separate 
antibody (Ab)  preparations to the C  and V  regions of L 3x5  (anti-C~  15  and anti-V~  16 , 
respectively). With these Ab preparations and a25I-labeled L 31~, two radioimmunoas- 
says were developed to measure the frequencies, in mice of different ages, strains, and 
immunization background, of serum Igs whose L chains have the respective antigenic 
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properties of the C  and V  regions of L 315. The V  region of L ~1~ has recently become 
of particularly keen  interest because its amino acid sequence  (5)  corresponds almost 
exactly to the recently determined deoxynucleotide sequence of the first V  gene cloned 
from embryonic mouse DNA  (8). 
Materials  and  Methods 
Antigens and Antisera.  Dextran 1355S was generously provided by Allene Jeanes, U.S. Dept. 
of  Agriculture,  Peoria,  Ill.  Keyhole  limpet  hemoeyanin  (KLH)  was  purchased  from 
Schwarz/Mann  Div., Bectin, Dickinson & Co., Orangeburg, N. Y. Dinitrophenyl (Dnp) was 
conjugated to KLH as described (9); the protein had  11 Dnp groups/100,000 daltons of KLH. 
Goat antisera to M315 were obtained from Walter Gray, Gateway Immunosera Co., Cahokia, 
Illinois. Three lots were used (11272,  32474, and 31173), each from a different goat that had 
been repeatedly injected with mildly reduced and alkylated M315.  Each antiserum had been 
adsorbed with M460-Sepharose (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscata- 
way, N. J.). 
Immunizations.  8-Wk-old  mice  were  immunized  with  KLH  or  Dnp11-KLH  in  complete 
Freund's adjuvant (Difco Laboratories, Detroit, Mich.) at a  1:9 ratio (aqueous to oil phase) as 
described (10).  Animals received two 0.5-mg i.p. injections 1 wk apart and were tail-bled 1 wk 
after each injection. 
14-Wk-old BALB/c mice were primed with one subcutaneous injection of 10 fig of dextran 
1355S.  1 Wk later, they received the first of 5  i.p. injections at  1-wk  intervals of 100 #g of 
dextran. The animals were tail-bled 1 wk after the fourth, fifth, and sixth injections. 
Iodinations.  Myeloma proteins were labeled with carrier-free 125I (11).  Chloramine T  was 
used at  a  10-fold molar excess over IgA proteins, but  at  a  1:1  molar ratio to  iodinate L 3xs 
chains. Specific activities were usually 3-6  ×  l0  s epm//tg. 
Preparation  of the Fv Fragment.  The proteolytic Fv fragment of M315, consisting of just Vn 
plus VL domains was prepared as described (12). Fv preparations having <  1% intact L chains, 
were obtained with a yield of -- 20%. Fv was measured by absorbance at 278 nm (E~m,  15.0; 
tool wt, 23,000 daltons) (12). 
Myeloma Proteins, Immunoadsorbants, and Antiserum  Adsorptions.  The following myeloma proteins 
of the indicated H-chain class and L-chain type were used: M315 (a, ~k2), M460 (a, x), M 104E 
(kt,)~1), HOPC-1  (y2a, ~1), MPC-11  (T2b, x), M21  (vl, K), LPC-I (y2a, K), and J606 (y3, x). X- 
2, a hybrid protein with the H chain of M315 but the x-chain from MPC-11, was derived from 
the fusion of MOPC-315 and MPC-11 tumor cells  2 and was generously provided as the purified 
protein by G. Siebert. 
M315, M460, and M 104E were isolated as described (13-15). J  chain was the kind gift of Dr. 
Marian Koshland (U. of California, Berkeley), who isolated it from  MOPC-315  serum  (16). 
M21,  MPC-11,  LPC-1,  and  HOPC-1  were  purified  by  gel  filtration  on  Sephadex  G-200 
(Pharmacia Fine Chemicals, Div. of Pharmacia Inc.) followed by chromatography on QAE- 
A50 at  pH  7.5  (or pH 9.1  for LPC-1)  (17).  Based on conductivity measurements,  myeloma 
proteins were eluted from QAE-A50 at the following molar concentrations of NaCI (indicated 
in parentheses): HOPC-1  (0.21),  M21  (0.27),  LPC-1  (0.34),  and MPC-11  (0.43). 
To remove Abs to a-chains and Abs that cross-reacted with ~l-chains, goat antiserum to L 315 
was passed successively over (a) M460-Sepharose (M460-S), with 2.1 mg M460/g Sepharose 4B 
(S), and (b) M104E-Sepharose (M104E-S), with 1.5 mg M104E/g S; 1 g adsorbant was used for 
0.4 ml antiserum. Proteins were conjugated to S as described (18). 
315  315  315  Antibodies  to  the  Constant  and  Variable  Regions  of L  :Anti-eL  and Anti-VL  .  Antibodies to 
315  315  M315 were separated into anti-CL  and anti-VL  with a  column of Fv-Sepharose (Fv-S): 1.2 
ml of anti-M315 was passed (after adsorption with M460-S and M104E-S) through  1 g of Fv- 
S with 4.6 mg Fv/g S. After an initial incubation for  15 min at 25°C, pass-through fractions 
with A27s >  0.08 were pooled to constitute anti-C~,  aS. 
After washing the column thoroughly (until A278 was <  0.015), 2 column volumes of 0.23 M 
glycine-HCl, pH 2.5, was added. Fractions with pH below 4 were collected until the absorbancy 
at 278  nm was no longer detectable (--- 1.5 column volumes). The eluted material, anti-V[  x5 , 
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was promptly neutralized with 1/10th vol of 2 M  Tris-HCl, pH 8.0, and dialyzed extensively 
against 0.02 M  Tris-saline, pH 8.0. The anti-V~,  TM  recovered from  1 ml of anti-h2 processed in 
this manner  had 0.65  A27s U. To avoid Fv denaturation, the Fv-S was not pretreated with 
glycine-HCl, and each Fv-S column was used only once. 
Preparation of IgG.  IgG  was  isolated  from  normal  mouse  serum  by  starch  block  zone 
electrophoresis followed by two gel filtrations on Sephadex G-200 (19).  Over 90% of the first 
retarded peak, taken as IgG, migrated in sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (SDS-PAGE)  (nonreducing conditions) as a  band of ~-  150,000  daltons. To deplete 
some IgG preparations of ~2-containing molecules, they were adsorbed (usually in lots of 12 
mg) over anti-)~2-S, prepared by coupling S with the Ig fraction obtained by ammonium sulfate 
precipitation (40% saturation) from goat antiserum to L 315 (previously adsorbed with M460-S). 
As a control, a portion of the same mouse IgG preparation was adsorbed with S coupled with 
a similar Ig fraction (40% ammonium sulfate precipitated) from normal goat serum (NGS-S). 
Preparation of L Chains.  L 315 was isolated from purified M315  as described (20).  L  chains 
were  also obtained  from  normal serum  IgG preparations  (see  above), some of which  were 
previously adsorbed with anti-%2-S or normal goat serum  (NGS)-S. The unbound IgG from 
both adsorbants (i.e., pass-through fractions) were treated in the same way: at 20 mg/ml they 
were  reduced  with  25  mM  dithiothreitol  (DTT)  in  6  M  urea-0.2  M  Tris-HC1,  pH  8.2, 
carboxymethylated with 57.5 mM iodoacetic acid, and dialyzed for 3 h against 6 M  urea-1 M 
acetic acid before being chromatographed in that solvent on a  Sephadex G-100 column.  L- 
chain fractions, selected to minimize contamination with H  chains, were dialyzed against 50 
mM acetic acid, lyophilized, and rechromatographed on a Sephadex G-100 column under the 
same conditions. 
To  prepare  soluble  L  chains  for  carboxypeptidase A  (CPA)  digestion,  the  lyophilized, 
carboxymethylated (CM)-L chains were taken up in 6 M urea-0.33 M NH4HCO3 and dialyzed 
against 0.2-0.3  M  NH4HCO3,  pH  8.0.  L  chains were  measured by absorbance at  278  nm 
(EI~m  ----  ll.0) (20). 
CPA Digestion of L Chains.  Soluble CM-L chains in 0.2-0.3 M  NH4HCO3  (typically at 4 
mg/ml) were digested with Worthington bovine pancreatic CPA (diiosopropyl phosphofluori- 
date-treated) at an enzyme:L chain ratio (wt/wt) of ~  1:1,000.  Digestion was stopped after 8 
h at 37°C by lyophilization. The enzyme alone and CM-L chains alone served as controls. The 
lyophilized digests were dissolved and trichloroacetic acid (TCA) was added to 10%. The TCA- 
soluble material was lyophilized and analyzed for released amino acids on a  Durram D  500 
analyzer(Durrum Dioxex, Sonneyvale, Calif.). Preliminary controls showed that the recovery of 
free amino acids in the TCA step was 89-92%. 
Radioimmune-lnhibition Assay to Measure Igs with ~2-Chains.  To measure the amount of Ig with 
%2-L chains, various sera or purified Ig fractions were tested for ability to inhibit the reaction 
between  anti-C[  x5 or anti-V[  is  and  125I-L315 in  a  double  Ab  radioimmunoassay  (21).  For 
standardization, an inhibition curve was obtained with purified M315, centrifuged at  100,000 
g  for  1 h  to eliminate aggregated protein.  Maximally, between  75 and  80%  of 125I-L315 was 
bound by anti-C[  15 and 50% by anti-V[  15. The background, using NGS instead of Abs to L 315, 
was 1-3% and the assay could detect the equivalent of 80 ng M315/ml. The standard deviation 
among replicate samples was  +  0.8%  of the added 125I-L  31s. The frequency (percent) of IgG 
with %2-L chains was calculated as 100 times the ~tg-Eq of M315//xg of IgG, where pg IgG was 
1%  based on sample absorbancy at 278 nm (El cm  =  14.0) and the/~g-Eq M315 was determined by 
comparing inhibition by the sample with inhibition by protein M315. 
Results 
The Radioimmune Inhibition Assay for Measuring %2-Associated Ig.  To  search  for %2- 
containing Igs, it was particularly useful to employ (a) an antiserum that was raised 
against the intact M315 molecule (or its Fab fragment) and (b) the isolated L m5 chain, 
rather  than  intact  M315,  as radiolabeled antigen  in  the assay. The  first precaution 
increased the probability that the antiserum recognized the %2-L chain when  it was 
part  of an  intact  Ig,  and  the  second  assured  that  the  assay was  restricted  to  Abs 
against %2-determinants, not  H  (immunoglobulin heavy) chain  (or idiotypic) deter- TOM  COTNER  AND HERMAN  N. EISEN 
TABLE I 
Specificity of the Radioimmunoassay  for Igs with L Chains with the C 
Domain of L 315. 
Inhibitors 
Experiment  Inhibition§ 
number  Substance  Amount* 
ng  % 
1  None  (0) 
Fv(VL  a15 +  VI.I  siS)  75  0 
L  al5  75  84 
2  None  (0) 
L  sis  8  12 
J chain  450  0 
3  None  (0) 
M315 (a,h2)  3  12 
M315 (a, h2)  80  91 
X-2 (315H,x)  3,800  0 
HOPC-I (72,,h  I)  4,000  0 
104E ~, hi)  4,000  0 
M460 (a, K)  2,500  0 
MOPC 21 0% ~)  2,500  0 
MPC- 1  l (72b,~)  2,500  0 
LPC- 1 (~,z,,  ~)  2,500  0 
4  None  (0) 
M315  2  12 
M315  20  71 
J606 ('/2,g)  1,330  0 
* All tubes had anti-CL  ~15 as antibody and l~ZI-La15  (15 ng; 33,000 cpm). In the 
uninhibited controls, the percent of ~2SI-LS~5  bound was 23, 23, 19, and 36% 
for experiments  1, 2, 3, and 4, respectively. 
:l: Amount  given indicates  highest  levels tested  for negative  controls;  lesser 
amounts also gave no inhibition. 
§ Zero indicates binding within  :t:  1.5% of the amount bound by the unin- 
hibited control (represented by zero in parentheses). 
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minants. The value of the second precaution was evident in some early trials where 
the  presence  or  absence  of anti-a-chain  Abs  did  not  alter  the  anti-M315  serum's 
activity or specificity in the radioimmunoassay for ~2-chains. 
The specificities of the Abs used to assay for Igs with C~  15  and V~  1~  are shown  in 
Tables  I  and  II.  In  the  assay  for  C~,  15  (Table  I),  75  ng  of Fv  fragment  was  not 
inhibitory, whereas the same amount of L 315 inhibited 85%. In contrast, the assay for 
V~  15 was inhibited to about the same extent by Fv and L 315 (Table II). Neither of the 
~,l-proteins  tested  (HOPC-1  and  104E)  inhibited  the  assay  for C~  15  reaction,  and 
104E  did not inhibit the assay for ~7315  VL  . Neither assay was inhibited by M460  (a, x), 
by purified myelomas of the 71-, ),2a-, or 72b-subclasses, or by X-2  (a, ~), a  protein 
that  bears the M315  H  chain  and  is produced by a  hybrid cell (MOPC-315/MPC- 
11)  (Materials and Methods). The assay for C~  t5  was also not inhibited by a  myeloma 
protein of the T3-class (,J606), or by J  chain, a  potential contaminant of L zl~ (15). 
Agreement  between  the Assays for CSL  15 and VSL  1~.  To determine whether the assays for 
C~  15  and  V~  ~5  were  quantitatively  consistent,  both  were  used  to  measure  M315  in 
various  samples.  The  results  of  both  assays  were  in  close  agreement  (Table  III) 
whether the samples tested were sera from mice with growing MOPC-315  tumors or 1392  ~.2-LIGHT  CHAINS  IN  NORMAL  MOUSE  IMMUNOGLOBULINS 
TABLE  II 
Specificity of the Radioimmunoassay  for Igs with L Chains with the V 
Domain of L 315. 
Inhibitor tested 
Experiment  Inhibition§ 
Number  Substance  Amount:~ 
ng  % 
1  None  (0) 
Fv  75  44 
L 31~  75  50 
L 31'~  500  90 
M315 (a,~2)  14  16 
M315 (a,~.2)  82  48 
M315 (a,,~2)  5,450  92 
M460 (a,K)  5,450  0 
104E ~,?~  1)  5,450  0 
2  None  (0) 
X-2 (315H,a¢)  1,900  0 
MOPC-21  (yl,x)  2,500  0 
LPC-1  (ysA,x)  2,500  0 
MPC- 11  (ysB,I¢)  2,500  0 
* All tubes had anti-VL  a15 as antibody and 125I-L315 (15 ng;  18,000 cpm). In 
the uninhibited controls the percent of 125I-Laas bound was 26 and  19% for 
experiments 1 and 2. 
:~ Amount  given  indicates highest  levels  tested  for  negative controls;  lesser 
amounts also gave no inhibition. 
§ Zero indicates binding within  +  1.1% of the amount bound by the unin- 
hibited control. 
TABLE  III 
Agreement Between the Assays for CL  a15 and VL  315 
Concentration of  Concentration of 
Sample tested  VL315  CL315 
Ratio 
VL31fCL  3:5 
mg/rnl  mg/ml 
MOPC-315 serum  3.85  3.4  I. 13 
MOPC-315 L.K. serum*  0.15  0.13  I. 15 
M315:1:  0.53  0.58  0.91 
average:  1.06 
* Serum  from  animals  bearing  MOPC-315  L.K  tumor,  a  subliue  of  MOPC-315  that 
produces low levels of M315. 
~" The M315 used here was isolated independently of the M315 used to construct the standard 
calibration curves. 
purified  M315  isolated  independently  from  the M315  preparation  used  to construct 
the standard  inhibition curve. 
Normal Mouse Serum Igs with ~2-Chains.  To determine  whether  L  chains with the C 
domain  of L 315  (i.e.,)~2-chains)  occur  in  normal  mice,  sera  and  purified  Ig  fractions 
were tested for the ability to inhibit the reaction between anti-C~  x5  and  lzSI-L315.  The 
results, summarized  in Table  IV, showed  suprisingly high serum  levels of)k2.  Serum 
samples  from  adult  BALB/c  mice  behaved  as  though  they  had  (on  the average)  80 
#g/ml  of Igs with )k2-chains. Similar high values were found in serum  from C57B1/6, 
AL/N,  and  NZB  mice and  much  lower  values  (15-30 #g/ml)  were  found  in  SJL/J, TOM  COTNER  AND  HERMAN  N.  EISEN  1393 
TABLE IV 
Levels in Sera  from Different Mouse Strains of lmmunoglobulins with Light Chains having the C and V 
Domains of L 315 
Strain  Age 
CL  315  VL  315 
Average  Range  Average  Range 
wk  #g/ml  #g/ml  ~g/ml 
AL/N  15  140 -i- 88 (4)*  86-272 
NZB  15  97 ±  24 (4)  76-119 
BALB/c  15  85 ±  36 (15)  23-140  13.8 ±  6.2 (6)* 
A/J  15  76 ±  48 (6)  37-154 
LP/J  >20:[:  67 (2)  65-68 
C57B1/6  15  66 ±  23 (8)  36-92  11.2 ±  2.3 (3) 
C57B1/10  15  61  -e 25 (4)  44-98 
I/LnJ  >'20  59 ±  19 (3)  39-79 
B10.D2  15  56:1:10 (3)  48-67 
MA/MyJ  >'20  54 ~  17 (3)  36-70 
BAB/14  15  55 (pool of 10) 
LG/J  >'20  51  ±  28 (4)  23-88 
CBA/J  15  50 ± 17 (5)  33-77 
SM/J  >'20  49 (2)  49,49 
C57Br  15  47 (2)  46,48 
STB/J  >'20  46 (2)  36,56 
SEC l/ReJ  >'20  49 (2)  46,53 
129/SV  >'20  46 (2)  44,48  6.7 (2) 
AKR/J  15  41 ±  9 (7)  27-55 
RF/J  15  38 ±  7 (7)  29-46 
Au/SSJ  >'20  35 (2)  22,48 
BDP/J  >'20  36 (3)  17-63 
C3H.OH  15  3I ±  7 (3)  23-38 
SWR/J  >'20  29 ±  10 (8)  14-43  2.7 (2) 
C3H/HeJ  15  28 ±  6 (9)  21-34 
DBA/2J  >20  28 ±  9 (10)  8-39  3.3 ±  0.5 (4) 
SjL/j  >'20  25 ±  13 (5)  11-46  3.3 (3) 
SEA/GnJ  >'20  24 ±  10 (4)  17-39 
CE/J  >'20  23 (pool of 5)  3.4 
C58/J  >20  20 (2)  18,21 
RIII/2J  >20  20 (2)  16,24 
BSVS  >'20  19 (2)  10,27 
P/J  >'20  15 ±  6 (3)  10-21 
l~g/ml 
4.6-18.5 
8.5-12.6 
6.2,7.1 
2.6,2.9 
* Numbers in parentheses  are the number of mice assayed;  +  refers to standard deviation. 
Mice >20 wk old were retired breeders. 
DBA/2,  and BSVS strains. Several other strains had intermediate values. A  prelimi- 
nary study showed  that  in BALB/c  mice,  the levels of Igs with ~2-chains increased 
with age from ~  30 #g/ml  at 4  wk to -~ 80/~g/ml between  12 and  15 wk. 
After  starch  block  electrophoresis,  >90%  of the  inhibitory activity of serum  was 
found  in  the  Ig-enriched  fractions,  and  after  gel  filtration  on  Sephadex  G-200, 
inhibitory activity was  found  only in the  void  volume and in the  IgG-rich fraction 
(data  not shown).  The  inhibitory activity of purified BALB/c  IgG indicated that  it 
had 0.7%  (range 0.48-0.96%)  ~2-containing Igs. This value is highly significant (P < 
0.001), as the inhibitory activity of purified ?~1- and r-myeloma proteins was negligible 
(corresponded  to <0.03%). 
Two observations strengthened  the probability that  the serological  test  identified 1394  X2-LIGHT CHAINS IN NORMAL MOUSE IMMUNOGLOBULINS 
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Fro.  1.  Comparison of M315  and  IgG  from  normal  serum  of C57BL/6  mice  as  inhibitors  of 
anti-C[  1~ antibodies.  Inhibition with the normal serum IgG was fitted to the standard inhibition 
curve obtained with purified M315 (O) by placing the third of five IgG values (shown by arrow) on 
the standard curve. 
)k2-chains in normal Igs: (a) purified IgG inhibited >90% of the reaction between 125I- 
L 315 and anti-C~,  15 and (b) the inhibition curves obtained with purified IgG and M315 
were essentially indistinguishable (Fig.  1). If the inhibitor in normal IgG differed from 
L 3z5, the slope of its inhibition curve would probably have differed from that of M315. 
Normal  Mouse  Serum Igs  with  L  Chains Having  a  V  Domain like  that  of L 3x~.  The 
radioimmune inhibition assay with anti-V~  15 showed that molecules with the V region 
of L 3z5 (V~  15)  are present in BALB/c serum at a concentration, in M315 equivalents, 
of  10-14  ~g/ml  (Table  IV).  Because this  value  is only one-sixth  that  of )~2-chains 
recognized with anti-C~  15, it appears that the V  domains of most )~2-chains in normal 
Igs differ from the V  domain of L 315. 
Increase in Caz  15 and V3r  z~ upon Immunization with Dnp-KLH.  Because M315, the only 
)~2-myeloma protein  known  so  far,  has  Dnp-binding  activity,  we  investigated  the 
effect of immunization with Dnp-KLH on serum )k2-1evels. As can be seen in Table 
V, serum from BALB/c, C57B1/6,  and AKR mice immunized with Dnp-KLH had 
3-21-fold greater ~2 levels than preimmune sera. Control sera from mice immunized 
with KLH alone also increased, but the change over preimmune serum was three- to 
fivefold greater for the Dnp-KLH-immune than the KLH-immune group. The mice 
were 6-8 wk old at the start of the experiment and time-course studies showed that in 
conventionally raised mice, )k2-concentrations did not level off until  12-15 wk. Thus, 
some increase in each group was probably due to aging rather than to immunization. 
The average levels of V~  z~  (Table V) in serum from BALB/c, C57B1/6, and AKR 
mice  immunized  with  Dnp-KLH were  also  substantially  higher  than  the  level  in 
serum from KLH-immunized animals or serum from unimmunized  15-wk-old mice 
(Table IV). In one experiment, the level of 92/~g/ml in pooled sera from Dnp-KLH- 
immunized  BALB/c  mice  was  10  times  higher  than  the  level  in  serum  from  the 
control KLH-immunized BALB/c mice (Table V, group 2). 
To determine if the results of the )k2 assay were due to cross-reaction with naturally 
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VL,'I~II  Group  Strain and age*  Immunogen  Ratio  (Im-  Ratio  (DNP-  (Immune) 
Pretmmune  |mmune  munel/fPre- 
K1,H)/(K1,H) 
immune) 
wks  p.g/ml  A~g/ml  p.g/ml 
I  BALB/c¢ (7)  KLH  27.3  31.0  l.t  ND 
(22-43)  (15-56)  3.0 
Dnp-KLH  31.0  102.5  3.3  28.4 
(22-34)  (62-145)  (23- 34) 
2  BALB/¢§ (10)  KLH  ND  56  7.6 
(Pool of 5)  (Pool of 5) 
Dnp-KLH  ND  284  92 
(Pool of 5)  (Pool of 5~ 
3  C57BL/6:~ (8)  KLI-I  53  83  1.6  ND 
(41- 70)  (38-140)  4.1 
Dnp- KLH  21,7  144  6,6  31.7 
(16-28)  (74-218)  (28-39) 
4  AKR~ (6--7)  KLH  10.6  41.8  3.9  ND 
(7-14)  (25-55)  5,5 
Dnp-KLH  11.4  245  21.5  49 
(8-14)  (1~-4oo) 
5  BALB/c (14)  ~xtran  Oa  49  0.7 
(47-89)  (40-79) 
ND -  not done. 
* Age when immunization  was begun  is in parentheses;  10 mice per group (5 with Dnp-KLH, 5 with KLH). 
:~ The immunization  protocol  in groups  1, 3, and 4 employed  0.5 mg of antigen  in [ :9 ratio with complete  Freund's adjuvant  as described in 
Materiah  and Methods. 
§ Mice were injected with 100 wg in complete  Freund's adjuvant,  then  100 ~tg in incomplete  Freund's adjuvant  on day 7,  100 ~.g in saline on 
day 14, and bled 1 wk later. 
II Numbers  are  averages  per group  of five  mice  (with  range  of values  for individual  mice  in  parentheses).  For dextran  injections  (saline, 
subcutaneously),  see Materials  and Methods. 
to elicit Xl-containing Abs in this strain (22). The ratio of A1/A2 in normal BALB/c 
serum  is 3.6/1  (T.  Cotner.  Unpublished observations).  In sera from  dextran-immu- 
nized BALB/c mice, the A1/A2 ratio was 6.6, and there was no increase in the absolute 
concentration of A2  (Table V, group 5). 
CPA Digestion  of L  Chains.  To evaluate the validity of the serological results by an 
independent method, CPA-digestion was carried out. This approach took advantage 
of differences in the carboxy-terminal amino acids of •-,  AI-, and A2-chains (cysteine, 
serine,  and leucine,  respectively).  By reacting reduced  L  chains with iodoacetate as 
the alkylating agent, a negative charge was placed on the terminal cysteine of r  and 
the penultimate cysteines in X1 and A2. At pH 8, amino acids with negatively charged 
side  chains  are  released  very  slowly  by  CPA  (23).  Thus,  r  chains,  which  occur 
naturally in -~  10-20-fold  excess over h-chains  (1, 8), are not significantly attacked, 
allowing detection of amino acids released from proteins that comprise a small fraction 
of the L-chain preparation.  Leucine was detected at a  level of 0.016-0.018  mol/mol 
of L chain in the CPA digests of three L-chain preparations, and a  few other amino 
acids were  found at about one-half this level.  As expected,  the serine of A1  was not 
obtained at a  significant  level because carboxy-terminal  serine is poorly released by 
CPA, especially  if the penultimate residue is also a slowly released amino acid  (23). 
To  determine  if all  of the leucine  released  by  CPA  was  due to ~2,  L  chains  were 
isolated from a BALB/c IgG preparation that had been adsorbed with either anti-A2- 
Sepharose or, as a control, with S coupled with NGS-S. The level of leucine released 
by  CPA  from  the  anti-X2  adsorbed  L  chains  decreased  about  twofold  (to  the 
background level of the other amino acids), whereas in the L chain from Igs that had 1396  ~2-LIGHT CHAINS IN NORMAL MOUSE IMMUNOGLOBULINS 
been  passed  over the  control  S  (NGS-S),  the  leucine released was  unchanged  (1.7 
tool/100 mol L chain): the difference in level of leucine released was thus -  0.7 mol 
of leucine/100 tool of L chain. This value may be corrected approximately twofold by 
taking into account the 50% yield of leucine by CPA digestion of L 315 (reference 20 
and  T.  Cotner.  Unpublished  observations).  Hence,  the  CPA  digestion  provides 
independent support for the serological demonstration that ~2-chains account for -~ 
1% of the L chains in normal serum Igs of BALB/c mice. 
Discussion 
This study shows  that  in mice of the BALB/c and several other strains  =  1% of 
serum Igs have L chains of the ~2-type, confirming earlier tentative serological tests 
with  anti-~2-antiserum  whose  specificity was  not  fully  established  (5).  The  same 
frequency has  been  found  by analyzing the  carboxy-terminal peptides  cleaved by 
trypsin  from  L  chains  of normal  mouse serum  Igs  (7).  The  1-2%  value  has  been 
further reinforced by the recent finding that  at  least  three, and  probably four, ~2- 
containing myeloma proteins have been identified by screening 260 sera from BALB/c 
mice with myeloma tumors. 3 Because sera from all of the 35 inbred strains tested had 
~2-chains, ~2 clearly represents an L-chain isotype; i.e., ~2 is not an allelic variant of 
~,1. 
The strain survey revealed large differences in serum ~2-1evels, ranging from 15-30 
/.tg/ml  of Igs  with  ?~2-chains  in  some  strains  to  140  /.tg/ml  in  AL/N  mice.  The 
differences are not  associated with differences at  the H-2 complex, as BALB/c and 
NZB  (both  H-2  d)  had  high levels of ~2 whereas DBA/2  (also H-2  d)  had  low levels 
(Table  IV).  Although  differences in  ~2  levels might  reflect  differences in  total  Ig 
(which might be IgCH linked, [24]), control by genes in the heavy chain linkage group 
cannot explain  differences between BALB/c and  C3H/He  (both  lg-l")  or between 
C57B1  and SJL or C58  (all lg-lb). The genetic basis for regulating the expression of 
this h-chain isotype may be approached through further study of the large differences 
in ~2-1evels in various strains. 
The several approaches used to establish the frequency of~2-chains in mouse serum 
Igs were all based on distinctive serological and chemical features of the C domain of 
L a15. In contrast,  the  frequency of L  chains with  the V  domain of L a15  (i.e., V~  1~) 
could only be measured serologically, Nevertheless, the validity of the assay for V~  1~ 
is strongly supported by the agreement between this assay and  the one for C~  15  in 
measurements of myeloma protein M315, either in serum of tumor-bearing mice or 
as a purified protein (Table III). By the serological test, L chains with V~  t5  appeared 
to be sixfold less abundant  in normal serum Igs than L chains with the C  region of 
L atS. The radioimmunoassays thus divide ~2-chains  into at  least  two subsets:  those 
whose VL domains resemble (or are identical) with V~  1~ and those whose VL domains 
differ from V~  15. We assume  (but have not  demonstrated)  that  the L  chains which 
react with  anti-V~  15 are a subset of all ~2-chains. 
Comparison of the amino acid sequences in L a~ and in ~l-chains shows that their 
V  regions are  much  more alike  than  their C  regions  (4),  and  the V  regions of ~1 
chains from myeloma proteins show remarkably little variation (3). From the radioim- 
munoassay with anti-V~  15, it appears that the V  regions of-  85% of ~k2-chains differ 
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from V~,  15. Though this observation could mean greater variation in the V  domains 
of h2- than of ~l-chains, two uncertainties  must be emphasized:  (a)  it is not known 
whether the V  domains of ~l-chains  in normal serum Igs are as restricted in amino 
acid sequence as the V  domain of)~l-chains from myeloma proteins;  (b) the extent of 
amino acid sequence variations in the )~2-chains that differ from L aa5 is unknown. 
It  is also far from certain  that  all chains  with  inhibitory activity in  the radioim- 
munoassay for V~  15 have precisely the same amino acid sequence as V a15 . If they did, 
this  finding would  mean, somewhat surprisingly,  that  the L  chains of ~  1 in  1,000 
serum Ig molecules in BALB/c and some other mouse strains are identical with L aaS. 
It is alternatively possible that the serological assay detected a set of L chains whose 
V  region  amino acid  sequences  are  very similar but  not  completely identical  with 
each other or with L 315. Nonidentity of these sequences would fit the recent finding by 
Tonegawa et al. (8), that although the deoxynucleotide sequence of a Vx gene, cloned 
from mouse embryonic DNA, corresponds almost exactly to the amino acid sequence 
of V~  15  (from  position  1 to  98)  there  are  differences  at  four  positions,  one  in  the 
framework and  three  in  the  third  hypervariable region.  The V  gene sequenced  by 
Tonegawa et al.  (8), probably represents the germ-line gene for the V  region of)~2- 
chains, from which the gene for V~  15  was probably derived by a somatic mechanism 
(mutation  or  recombination).  Other  variants,  more  or  less  similar  to V~  15,  could 
account for the V  regions of the entire set of)~2 chains, with one-sixth of the variants 
so similar to V~  15 as to be serologically indistinguishable  from it. 
Differences in responses to immunization with Dnp-KLH and with KLH suggest 
that  Dnp-proteins are capable of preferentially stimulating )~2-producing cells. This 
observation  is  in  accord  with  the  high  affinity  of  protein  M315  for  Dnp  and 
trinitrophenyl  ligands  (25).  The preferential  production  of X2-containing Abs, and 
increasing refinements in procedures for producing and selecting clones of fused cells 
(hybridomas)  that  make  particular  Ig chains,  may  eventually  make  it  possible  to 
analyze directly amino acid  variations in V  regions of)~2-1ight chains  from normal 
(rather than myeloma) Igs. These variations, viewed in relation to the DNA sequence 
of the embryonic (probably the germ-line) Vx2 gene, should help clarify the basis for 
the generation of immunoglobulin diversity. 
Summary 
The  amino  acid  sequence  of the  constant  (C)  domain  of the  light  chain  of the 
mouse myeloma protein  M315  has not  been identified so far in any other myeloma 
protein.  In  this  study,  serological  analysis with  antiserum  to  the  C-domain  of this 
light chain  (L  3a5) showed that  ~  1% of Igs in normal mouse serum have L  chains of 
the  L 315  type  (called)~2).  Corroborative  evidence  was  obtained  by analysis  of the 
carboxyterminal amino acid removed from normal light chains by carboxypeptidase 
A. A survey of 35 inbred mouse strains showed that all had )~2; the serum level of Igs 
with )~2-chains ranged from ~  140 ~g/ml in AL/N mice to ~  25/~g/ml in SJL, BSVS, 
and eight other strains. In accord with the anti-Dnp activity of M315, sera from mice 
immunized  with  Dnp-KLH had  three-  to  fivefold more )~2  than  sera  from control 
mice immunized with KLH. 
It was also possible to measure serum  immunoglobulin  molecules bearing the )k2 
variable region of M315  (V~,as). In BALB/c sera, the concentration ofV~  15  was about 
sixfold lower than that measured for X2. Thus, )~2-chains are divided into at least two 1398  X2-LIGHT CHAINS IN NORMAL MOUSE  IMMUNOGLOBULINS 
subsets:  those  whose V  domain  is  indistinguishable  from V~,  1~  and  those whose VL 
differs  from V~  15. A  10-fold increase  in V~  15  was obtained  by immunizing BALB/c 
mice with Dnp-KLH. The relationship of the VL domains of normal immunoglobulin 
)~2-chains  to  the  embryonic  Vx  gene  recently  sequenced  by  Tonegawa  et  al.,  is 
discussed. 
Received for publication  21June 1978. 
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